This phase I study consisted of two parts. Part 1 was a single-center, open-label, randomized, pilot study. Part 2 was a multicenter, randomized, double-blind, pivotal study to compare HLX15-IV with reference daratumumab.

Healthy Chinese male participants aged 18 to 60 years were enrolled and randomized in a 1:1:1:1 ratio to receive a single intravenous infusion of HLX15-IV (HLX15-IV group), US-sourced daratumumab (US-dara group), European Union-sourced daratumumab (EU-dara group) or China-sourced